Buy Heroin Dabrowa Gornicza

__________________________

📍 Verified store!

📍 Guarantees! Quality! Reviews!

__________________________

▼▼ ▼▼ ▼▼ ▼▼ ▼▼ ▼▼ ▼▼

▲▲ ▲▲ ▲▲ ▲▲ ▲▲ ▲▲ ▲▲

Buy Heroin Dabrowa Gornicza

Also known as pediatricians, these doctors collaborate with nurses, X-ray technicians, medical assistants, and other doctors such as emergency room doctors and surgeons to treat children. Home - Expert Doctors - Dr. James Osborne. O medicalZahar. Provider Info Gender: Female.

Bg Pharma Sp. z o.o. (Poland)

Buy Heroin Dabrowa Gornicza

It is believed to be one of the oldest cities in Poland, with roots tracing back to the 10th century. Chronic lymphocytic leukemia CLL is a type of blood cancer that affects many people worldwide. Those with CLL often experience enlarged lymph nodes, spleen, or liver, and symptoms such as night sweats, weight loss, and fever. This study will compare the efficacy of two different treatment combinations for participants with previously untreated CLL:. Participants in this study will receive either venetoclax and obinutuzumab, which is a standard first-line treatment, or a combination of sonrotoclax and zanubrutinib. The goal is to determine if the combination of sonrotoclax and zanubrutinib is more effective in treating CLL than venetoclax and obinutuzumab. The study includes approximately participants from across the globe. Participants will be randomly assigned to receive one of the two treatment combinations. The study primarily aims to compare how long participants live without their CLL worsening when treated with either combination. Diabetic Peripheral Neuropathy is a condition where high blood sugar levels cause nerve damage, especially in the legs and feet, leading to pain and discomfort. The study aims to test the safety and effectiveness of a new drug, LY, compared to a placebo. Participants in this study will be randomly assigned to one of four groups: three groups will receive different doses of LY, and one group will receive a placebo. The study is blinded, meaning participants and researchers will not know who is receiving the drug and who is receiving the placebo. The study will last approximately 24 weeks and will be divided into three periods. During these periods, participants will receive the assigned treatment and will be monitored for changes in their pain levels and overall well-being. Various assessments will be used to track their progress. This clinical trial focuses on individuals with chronic nerve pain due to shingles a viral infection causing a painful rash or a nerve injury. The study aims to compare the effects of NT injections to placebo injections in reducing this pain. Conditions covered include chronic nerve pain from shingles postherpetic neuralgia and chronic nerve pain from an injury to the peripheral nerves caused by surgery or trauma. The main goal is to determine if NT can effectively reduce pain compared to placebo. The trial lasts for weeks. Participants will receive either NT or placebo at one injection visit. The study is aimed at patients with idiopathic inflammatory muscle diseases, such as polymyalgia PM and dermatomyositis DM. It will test a drug called anifrolumab, administered by subcutaneous injection, in combination with standard treatment, and compare it with placebo, also in combination with standard treatment. The study aims to assess the effectiveness and safety of anifrolumab compared with placebo in patients with moderate to severe disease. All participants will continue to receive standard treatment. The study involves adults aged 18 to 75 years who have been diagnosed with polymyalgia or dermatomyositis according to the classification criteria. Participants must currently be taking a stable dose of medication such as prednisone or other drugs used to treat these conditions. Chronic Inflammatory Demyelinating Polyneuropathy CIDP is a rare nerve disorder that causes nerve swelling and damage, leading to muscle weakness, numbness, and a loss of reflexes. This clinical trial assesses the safety and effectiveness of a drug called batoclimab also known by its code IMVT in treating adults with active CIDP. The study involves participants with CIDP who will receive different doses of batoclimab administered under the skin subcutaneously. Participants will be divided into four different groups based on their current treatment or recent lack of treatment. Some groups will receive high doses, while others will receive lower doses. After this, a washout period of up to 12 weeks may occur to ensure no interference from other treatments. Following this, participants will be randomized assigned by chance to receive either batoclimab or a placebo during a week treatment period. Following the initial treatment, there will be an optional long-term extension up to 52 weeks, during which those in the study may continue treatment to assess long-term effects. Overall, the study lasts up to approximately weeks, during which the health and progress of participants will be closely monitored to evaluate the continued efficacy and safety of batoclimab in treating CIDP. The study will use a drug called anifrolumab, which will be compared with placebo. The aim of the study is to assess the efficacy and safety of anifrolumab in reducing skin lesions associated with lupus in adult patients who have failed or are intolerant to antimalarial therapy. The study will involve adult patients aged 18 to 70 years who have a confirmed diagnosis of SCLE. The diagnosis must be confirmed both clinically and histologically and must be demonstrated by specific measures of disease activity. Patients must not have active or past tuberculosis infection, severe or life-threatening systemic lupus erythematosus, or other active skin conditions that could interfere with the study. In addition, they must not have a history of repeated infections requiring hospitalization and treatment with intravenous antibiotics. Anifrolumab will be administered as a subcutaneous injection for a fixed period of time, comparable to placebo in the first weeks of the study. In the following weeks, all patients will receive anifrolumab. The study involves patients with various types of advanced solid tumors, including non-small cell lung cancer and hepatocellular carcinoma. The study will test BI alone and in combination with pembrolizumab. The study aims to see how safe and tolerable BI is and to determine the most effective dose of the drug for further clinical trials. Patients whose disease has progressed despite standard treatment will receive intravenous infusions of BI every three weeks, alone or in combination with pembrolizumab. The study is intended for people aged 18 and older with advanced, histologically confirmed solid tumors. It is important that patients have at least one measurable tumor and meet certain health criteria regarding organ function. The study will use different therapies, including alectinib, entrectinib, and durvalumab. Patients will be divided into different groups based on their results of cancer biomarker tests. The study aims to assess the effectiveness and safety of these therapies. Patients in the ALK-positive group will receive either alectinib or durvalumab. Patients who are positive for ROS1 will receive either entrectinib or durvalumab. An important goal of this study is to see how long patients remain free of progression of their disease and how long the response to treatment lasts. The study will also monitor side effects in patients and assess how the therapies affect the quality of life of patients. The study involves patients with non-small cell lung cancer NSCLC that is locally advanced or metastatic has spread to other parts of the body. The aim of the study is to compare the effectiveness and safety of treatment with the new drug DZD and chemotherapy based on a combination of platinum-based drugs. Patients will be randomly assigned to two groups. One group will receive DZD at a dose of mg, taken orally once a day, and the other group will undergo chemotherapy with the drugs pemetrexed and carboplatin. In the case of the chemotherapy group, patients can be treated for up to 6 cycles, after which they can continue taking pemetrexed unless the disease gets worse. The main aim of the study is to assess progression-free survival, which is the period during which the cancer does not get worse, assessed by independent experts according to specific criteria. Patients will be monitored for up to about 34 months to assess the effectiveness of both treatments. The trial will compare two therapies: a combination of belrestotug and dostarlimab with pembrolizumab and placebo. The aim of the trial is to assess the efficacy and safety of dostarlimab and belrestotug therapy compared to pembrolizumab and placebo. The trial aims to determine whether the use of one drug combination will prolong disease-free survival and overall survival of patients compared to the use of the other drug combination. Patients are selected for the trial based on the presence of a locally advanced or metastatic tumor, after previously being diagnosed that their tumor has high expression of the PD-L1 protein. The trial will also assess the frequency of therapeutic response and other aspects related to the quality of life of patients. This trial investigates a new drug, designated as V, combined with pembrolizumab. Pembrolizumab aids the immune system in fighting cancer. The aim is to compare the effectiveness of V with pembrolizumab against a placebo with pembrolizumab. The study is randomized, meaning patients will be randomly assigned to receive either V with pembrolizumab or placebo with pembrolizumab. All participants will receive the drugs for up to a year, unless the disease recurs or unacceptable side effects occur. The study will evaluate various health aspects and quality of life, including disease-free survival, overall survival, and any side effects. Patients will be monitored over a long period to assess the long-term effects of the treatment. The study concerns non-small cell lung cancer NSCLC , a type of lung cancer that can take various forms. The therapy tested involves two drugs, atezolizumab and tiragolumab. The purpose of this study is to evaluate the effectiveness and safety of administering tiragolumab along with atezolizumab compared to a placebo combined with atezolizumab in patients who have already had their cancer surgically removed and have undergone platinum-based chemotherapy. Participants in this study will be divided into two groups. One group will receive atezolizumab combined with tiragolumab, while the other group will receive atezolizumab combined with a placebo. Both groups will receive their treatments through intravenous IV infusions. NSCLC is a type of lung cancer that has spread through the body or cannot be removed with surgery. Participants in this study must have been treated with no more than a platinum-based chemotherapy and an anti-PD- L 1 drug. For those with treatable tumor changes in their genes, they must have had at least one drug for that change, in addition to platinum-based chemotherapy. ADCs are designed to stick to cancer cells and kill them. The study also uses a drug called docetaxel , which is already approved to treat non-small cell lung cancer. Docetaxel is usually given to patients who have received prior treatment for cancer. The purpose of this study is to determine if sigvotatug vedotin works better than docetaxel in treating participants with non-small cell lung cancer. It will also examine what side effects occur when taking these drugs. During the study, participants will be divided into two groups. One group will receive sigvotatug vedotin on Days 1 and 15 of each day cycle. The other group will receive docetaxel on Day 1 of each day cycle. The study aims to find out if sigvotatug vedotin is more effective than docetaxel, and it will carefully monitor any side effects that happen during the course of the trial. A side effect is anything a drug does to the body besides treating the disease. This study focuses on advanced or metastatic non-small cell lung cancer. The cancer should be confirmed to have HER2 mutations. The study tests whether a drug called zongertinib also known as BI can slow down the growth of this type of cancer better than the currently available standard treatments. The standard treatment involves a combination of drugs: pembrolizumab , cisplatin or carboplatin , and pemetrexed. These drugs work together to target cancer cells. Participants will be randomly placed into one of two groups. One group will receive zongertinib regularly. The other group will receive regular infusions of pembrolizumab plus platinum-pemetrexed chemotherapy which includes cisplatin or carboplatin , and pemetrexed. Participants may remain in the study for up to 70 months. During this time, they will visit the study site about every 3 weeks. These scans will be more frequent in the first 18 months and then less frequent as the study progresses. Doctors will also monitor whether the cancer has spread and assess the overall health of the participants. Participants will be asked to fill out questionnaires about their symptoms and quality of life throughout the study. The study aims to discover if zongertinib is more effective at managing advanced non-small cell lung cancer compared to the standard treatment. This clinical trial is for patients with advanced non-small cell lung cancer NSCLC , a type of lung cancer that occurs when the cells in the lungs grow uncontrollably. The purpose of the study is to find out how safe and effective these drugs are when used together in patients who have progressed or relapsed after receiving first-line therapy that included immune checkpoint inhibitors ICIs. Participating patients will receive THIO by infusion on Days of each 3-week cycle, followed by Cemiplimab on Day 5, continuing this cycle until the disease progresses, severe side effects occur, or up to one year. Regular imaging will be done to assess the tumor size and how the treatment is working. Patients will have follow-up visits every 6 weeks for about 6 months and then at 9 and 12 months after the last dose. This trial aims to provide a new treatment option for patients with advanced NSCLC who have limited choices. This study includes participants with various solid tumors such as advanced solid tumors, locally advanced solid tumors, metastatic solid tumors, platinum-resistant ovarian cancer, post anti-PD-1 melanoma, cervical cancer that has had at least one prior line of therapy, neoadjuvant melanoma melanoma treated before the main treatment , neoadjuvant non-small cell lung cancer, post anti-PD-1 non-small cell lung cancer, and post anti-PD-1 small cell lung cancer. The goal is to evaluate the safety and tolerability of these combination therapies, as well as to find the most effective dose. Some participants may also receive surgery following the drug treatments. By conducting this study, researchers aim to improve the therapeutic options for patients with these specific cancer types and determine the best ways to use these new drug combinations for better outcomes. The study concerns patients with systemic lupus erythematosus SLE and examines the effectiveness and safety of obinutuzumab. Systemic lupus erythematosus is a chronic autoimmune disease in which the immune system attacks its own tissues and organs, causing inflammation and damage. The study drug is obinutuzumab administered intravenously at doses of 1, mg on the first day of the study and at weeks 2, 24 and The drug will be compared with a placebo. The aim of the study is to evaluate how well obinutuzumab works and how safe it is for patients with active, auto-antibody-positive systemic lupus erythematosus who are treated with standard therapy. It will also be assessed how often and what types of side effects may occur after administration of obinutuzumab and in the placebo group. Patients participating in the study must have a diagnosis of systemic lupus erythematosus and have clearly active disease despite standard therapy, which includes corticosteroids steroid drugs , antimalarial drugs and conventional immunosuppressants drugs that weaken the immune system. The clinical trial concerns patients with systemic lupus erythematosus SLE. The therapy that will be used includes a drug called telitacicept and a placebo. Telitacicept is a fully human protein that affects the B cells of the immune system, which are responsible for producing antibodies. The aim of this study is to evaluate the efficacy and safety of telitacicept in the treatment of moderately to severely active systemic lupus erythematosus. The study will analyze different doses of the drug, i. People aged 12 to 70 are eligible for the study. Patients are required to have had a diagnosis of SLE for at least 6 months, moderate to severe disease activity, and at least one positive serology during the eligibility period. Currently, they must use at least one standard treatment for SLE, such as oral corticosteroids, antimalarials or immunosuppressants. People with lupus erythematosus with symptoms of the central nervous system, lupus nephritis, other autoimmune rheumatic diseases, as well as people with active severe infections, uncontrolled diseases unrelated to SLE, or a history of cancer within the last 5 years cannot participate in the study. The study concerns patients with active systemic lupus erythematosus SLE. The therapy under investigation is GLPG, administered orally. The aim of the study is to evaluate the efficacy, safety and tolerability of GLPG when administered orally once daily for 48 weeks in adult patients with active SLE. The study will involve approximately participants. Participants will be randomly assigned to one of three groups: two groups will receive different doses of GLPG, and one group will receive a placebo. Patients will be assessed based on various indicators, such as the so-called lupus response index SRI-4 , disease activity assessment according to the British Lupus Assessment Group BILAG , and based on the number of tender and swollen joints. The study will also assess side effects, i. Adults aged 18 to 75 with a confirmed diagnosis of SLE and an appropriate level of disease activity are eligible to participate in the study. Excluded are patients with severe, active kidney disease, certain neuropsychiatric conditions associated with lupus, or those who have had certain serious infections. The effect of Afimetoran will be checked compared to placebo. Afimetoran also known as BMS The study aims to assess the effectiveness, safety and tolerability of Afimetoran. People aged 18 to 70 can take part in the study. To be eligible for the study, patients must have been diagnosed with lupus at least 12 weeks prior to the enrollment visit and meet specific SLE International Collaborating Clinics SLICC classification criteria. The primary goal of the study is to determine how many participants will achieve a response according to the SLE Responder Index 4 after 48 weeks. The study also provides for an extended period during which patients who initially received placebo will be able to receive Afimetoran therapy, which will allow further assessment of its long-term safety and effectiveness. In the study, participants will be randomly assigned to one of several groups: three groups will receive different doses of Afimetoran, and one group will receive a placebo. The study is double-blind, which means neither the patients nor the doctors conducting the study will know who is receiving the actual drug and who is receiving the placebo. Search by disease. Search by location. Currently, 20 clinical trials are being conducted in this city. Bydgoszcz , Poland. Lublin , Poland. Katowice , Poland. Warsaw , Poland. Szczecin , Poland. Olsztyn , Poland. Krakow , Poland. Gdynia , Poland. Kielce , Poland. Koszalin , Poland. Opole , Poland. Gliwice , Poland. Siedlce , Poland. Bytom , Poland. Sopot , Poland. Sosnowiec , Poland. Zabrze , Poland. Otwock , Poland. Grodzisk Mazowiecki , Poland. Tychy , Poland. Konin , Poland. Malbork , Poland. Skierniewice , Poland. Bystra , Poland. Radom , Poland. Nowy Targ , Poland. Piaseczno , Poland. Legnica , Poland. Sochaczew , Poland. Wadowice , Poland. Chojnice , Poland. Prabuty , Poland. Nadarzyn , Poland. Wieliszew , Poland. Zawadzkie , Poland. Ossy , Poland. Rybnik , Poland. Osielsko , Poland. Karczew , Poland. Lubin , Poland. Sztum , Poland. Kobylniki , Poland. Grzepnica , Poland. Poland , Poland. Trzebnica , Poland. Strzelce Opolskie , Poland. Gryfice , Poland. Leszno , Poland. Wejherowo , Poland. Zgierz , Poland. Skawina , Poland. This study will compare the efficacy of two different treatment combinations for participants with previously untreated CLL: Sonrotoclax BGB plus Zanubrutinib BGB Venetoclax plus Obinutuzumab Participants in this study will receive either venetoclax and obinutuzumab, which is a standard first-line treatment, or a combination of sonrotoclax and zanubrutinib. Clinical study on Polymyositis and Dermatomyositis using drugs. Clinical study on Cutaneous Lupus Erythematosus using drugs. Clinical study on non-small cell lung cancer using Alectinib, Entrectinib, and Durvalumab. Clinical study on non-small cell lung cancer using drugs. The study consists of three parts Part A tests different dose levels of THIO with Cemiplimab to identify the safest and most effective dose Part B randomly assigns patients to different groups receiving various doses identified in Part A to further evaluate safety and effectiveness Optional Part C tests a higher dose of THIO with Cemiplimab based on findings from Parts A and B Participating patients will receive THIO by infusion on Days of each 3-week cycle, followed by Cemiplimab on Day 5, continuing this cycle until the disease progresses, severe side effects occur, or up to one year. Study of Obinutuzumab in systemic lupus erythematosus. See more clinical trials in other cities in Poland:?

Buy Heroin Dabrowa Gornicza